The linked FDA records link this applicant to two premarket approval entries under P060011, both decided APPR. The original approval covers the C-FLEX Model 570C intraocular lens, a class 3 ophthalmic device under product code HQL, decided May 3, 2007. Supplement P060011/S045 covers the RayOne Galaxy and RayOne Galaxy Toric, filed February 12, 2026, amended June 26, 2026, and approved September 24, 2026 under product code MFK. The supplement is a panel-track labeling change affecting indications, instructions, shelf life or tradename. [1][2][5]

The C-FLEX approval and its stated scope

P060011 approved the C-FLEX Model 570C intraocular lens for primary implantation for the visual correction of aphakia in adults after removal of a cataractous lens by phacoemulsification, with the lens placed in the capsular bag. The record lists the applicant as Rayner Intraocular Lenses, Ltd. at a Hove, East Sussex address, with an ophthalmic advisory committee and no expedited review flag. [2]

RayOne Galaxy and RayOne Galaxy Toric

The approval order for P060011/S045 names the RayOne Galaxy (Model RAO605G) and RayOne Galaxy Toric (Model RAO615X) and lists product codes MFK and MJP. The order was signed for the director of the Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices and addressed to the applicant's regulatory affairs contact at a Memphis, Tennessee address. The SSED identifies the applicant at the Ridley Innovation Centre, 10 Dominion Way, Worthing, West Sussex, and records that the manufacturing facility inspection found compliance with the Quality System regulation then in effect. [3][5]

The FDA indication text describes RayOne Galaxy and Galaxy Toric as intraocular lenses for implantation following removal of a cataractous natural lens. The Toric version’s labeling also addresses corneal astigmatism. The same record describes the RayOne injection system as folding the lens and assisting its insertion. The detailed eligibility and power parameters belong in the original labeling. [1]

Documented design specifications

Rayner’s technical specification sheet describes both models as single-piece Rayacryl hydrophilic acrylic lenses with 26% equilibrium water content, a benzophenone UV-absorbing agent and a refractive index of 1.46. It lists an ABBE value of 56, a 12.5 mm full-lens diameter, a 6.0 mm biconvex optic and an Amon-Apple 360-degree square-edge design. These are the manufacturer’s published material and geometry specifications. [10]

Rayner's own announcement, published September 24, 2026, describes Galaxy as the world's first spiral IOL platform, developed with AI, with a non-diffractive spiral optic, and states more than 200,000 implantations across 75 countries since an international launch in 2024. These are the publisher's characterizations, not FDA findings. A patient information leaflet for the two models defines an intraocular lens as a small artificial lens placed in the eye during cataract surgery and refers readers to professional labeling. [8][9]

Applicant identity and collection context

The supplied collection holds two linked records, both premarket approvals with APPR decisions; the smaller record sample likewise shows two APPR decisions. These are counts of the filings retrieved as of the snapshot date, not measures of total portfolio, sales or safety performance. Rayner's portfolio brochure states the company is headquartered in Worthing, United Kingdom, and that Sir Harold Ridley implanted the first Rayner intraocular lens in 1949; that corporate description comes from the brochure, while the FDA records establish only the applicant name and filing addresses. [1][2][7]